Remeron (mirtazapine) Disease Interactions

There are 8 disease interactions with Remeron (mirtazapine):

Mirtazapine (Includes Remeron) ↔ Neutropenia

Severe Potential Hazard, Low plausibility

Applies to: Neutropenia

The use of mirtazapine has very rarely been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3 with associated signs and symptoms, e.g., fever, infection, etc.). Patients with preexisting neutropenia or agranulocytosis should be monitored closely during mirtazapine therapy for further decreases in white blood cell (WBC) counts. Mirtazapine should be discontinued in any previously, otherwise healthy patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count.

References

  1. Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995): 37-45
  2. "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.
  3. Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30

Mirtazapine (Includes Remeron) ↔ Renal/Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease, Renal Dysfunction

Mirtazapine is extensively metabolized by the liver. Both the parent drug and metabolites, some of which are pharmacologically active, are excreted by the kidney. The clearance of mirtazapine has been shown to decrease in patients with moderate to severe renal or hepatic impairment. Therapy with mirtazapine should be administered cautiously in such patients. Dosage adjustments may be necessary.

References

  1. Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995): 37-45
  2. Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996): 389-402
  3. "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.

Tcas (Includes Remeron) ↔ Pheochromocytoma

Severe Potential Hazard, Moderate plausibility

Applies to: Pheochromocytoma

Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines. Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas. Therapy with TCAs should be administered cautiously in patients with these tumors.

References

  1. "Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  2. "Product Information. Sinequan (doxepin)." Roerig Division, New York, NY.
  3. "Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals, Summit, NJ.
View all 12 references

Tetracyclic Antidepressants (Includes Remeron) ↔ Hypotension

Severe Potential Hazard, Low plausibility

Applies to: Ischemic Heart Disease, Dehydration, Hypotension, Cerebrovascular Insufficiency, Diarrhea, History - Cerebrovascular Disease, History - Myocardial Infarction, Vomiting

The use of tetracyclic antidepressants (TCAs) has occasionally been associated with significant orthostatic hypotension secondary to the drugs' alpha-1 adrenergic blocking effects. Therapy with TCAs should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke. Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with TCAs. Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.

References

  1. "Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.

Antidepressants (Includes Remeron) ↔ Mania

Moderate Potential Hazard, Moderate plausibility

Applies to: Mania, Bipolar Disorder

All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.

References

  1. Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988): 804-8
  2. Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993): s45-50
  3. Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991): 141-4
View all 17 references

Mirtazapine (Includes Remeron) ↔ Alt Elevations

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The use of mirtazapine has occasionally been associated with ALT (SGPT) elevations greater than three times the upper limit of normal. Although the majority of cases were reversible (some despite continued treatment) and not associated with other signs or symptoms suggestive of hepatic injury, therapy with mirtazapine should be administered cautiously in patients with preexisting liver disease. Periodic monitoring of liver enzyme levels is recommended.

References

  1. Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995): 37-45
  2. "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.

Mirtazapine (Includes Remeron) ↔ Hyperlipidemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperlipidemia

Mirtazapine may significantly elevate serum triglyceride and total cholesterol levels. Patients with preexisting hyperlipidemia may require closer monitoring during mirtazapine therapy, and adjustments made accordingly in their lipid-lowering regimen.

References

  1. "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.
  2. Davis R, Wilde MI "Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression." Cns Drugs 5 (1996): 389-402
  3. Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995): 37-45
View all 4 references

Mirtazapine (Includes Remeron) ↔ Seizures

Moderate Potential Hazard, Low plausibility

Applies to: Seizures

The use of tricyclic and tetracyclic antidepressants is associated with a risk of seizures. Only one case of seizure was reported with mirtazapine, a newer tetracyclic antidepressant, during premarketing trials involving nearly 2800 patients. However, the drug has not been evaluated in controlled studies of patients with a history of seizures. Therapy with mirtazapine should be administered cautiously in such patients.

References

  1. Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C "A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients." Acta Psychiatr Scand 93 (1996): 184-90
  2. Smith WT, Glaudin V, Panagides J, Gilvary E "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder." Psychopharmacol Bull 26 (1990): 191-6
  3. "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.

You should also know about...

Remeron (mirtazapine) drug Interactions

There are 734 drug interactions with Remeron (mirtazapine)

Remeron (mirtazapine) alcohol/food Interactions

There are 2 alcohol/food interactions with Remeron (mirtazapine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2014 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)